Exosomes Pipeline Outlook Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight

DelveInsight's "Exosomes Pipeline Insight 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Exosomes pipeline landscape. It covers the Exosomes Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Exosomes Pipeline? Click here to explore the therapies and trials making headlines @ Exosomes Pipeline Outlook Report [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Exosomes Pipeline Report

* On 10 October 2025, Rion Inc. announced a study is to evaluate the safety and efficacy of PEP-TISSEEL+ Standard of Care (SOC) compared to SOC-only treatment in 40 subjects (20 subjects PEP-TISSEEL + SOC and 20 subjects SOC only), specifically for the treatment of their non-healing DFU.
* DelveInsight's Exosomes Pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Exosomes treatment.
* The leading Exosomes Companies such as Celularity, EVerZom, Direct Biologics, Cambium Bio, Capricor Therapeutics, Aegle Therapeutics, Organicell, Evecxia, ArunaBio, Evox, Coya Therapeutics, ILIAS Biologics, EV Therapeutics, Nano24, and others.
* Promising Exosomes Therapies such as Olmutinib, Zofin, AGLE-102 , and others.

Want to know which companies are leading innovation in Exosomes? Dive into the full pipeline insights @ Exosomes Clinical Trials Assessment [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Exosomes Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Exosomes Pipeline Report also highlights the unmet needs with respect to the Exosomes.

Exosomes Overview

Exosomes are classified as small (30-150 nm), phospholipid bilayer extracellular vehicles (EVs), which are released by both eukaryotic and prokaryotic cells for the purpose of intercellular communication and signaling. Initially, exosomes were identified as EVs used for excreting unwanted cellular waste-however, studies found that exosomes are important molecular mediators in cellular communication through their ability to transport proteins, metabolites, and various nucleic acids across the body.

Exosomes Emerging Drugs Profile

* ExoFlo: Direct Biologics

ExoFlo is an acellular human bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle (EV) product produced with a proprietary EV platform technology by Direct Biologics, LLC. Containing signaling molecules from bone marrow MSCs, ExoFlo harnesses the anti-inflammatory and regenerative properties of bone marrow MSCs without the cost, complexity, and limitations of scale associated with stem cell transplantation. Preclinical studies of these extracellular vesicles secreted by bone marrow-derived mesenchymal stem cells (bmMSCs) suggest that they may have the ability to downregulate inflammation and upregulate tissue repair in humans. Currently, the drug is in the Phase III stage of its development for the treatment of Acute Respiratory Distress Syndrome.

* EXO-CD24: Nano24

EXO-CD24 (CovenD24), is an investigational drug being developed by Nano24. The company has developed a new anti-inflammatory drug, EXO-CD24, a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). CD24 inhibits the NF-kB pathway and the production of cytokines/chemokines. EXO-CD24 discriminates damage from pathogen-associated molecular patterns (DAMPs and PAMPs) and therefore does not interfere with viral clearance. EXO-CD24 was produced and purified from CD24-expressing 293-TREx cells. Exosomes displaying murine CD24 (mCD24) were also created. EXO-CD24 is the new immunomodulator with promising efficacy without interfering with pathogen clearance. Nano24 developed CD24-enriched exosomes, named EXO-CD24, as a targeted therapy for hyperimmune activation in the context of COVID-19. CD24, which dampens cytokines and chemokines production while not interfering with pathogen clearance, is of particular interest as a therapeutic agent for virus-induced hyper-inflammation and ARDS. EXO-CD24, and its mouse homolog EXO-mCD24, is a new precision nanotechnology that can target and prevent the cytokine storm in the lungs. Nano24 is developing a pipeline of CD24-based exosomes aimed at treating COVID-19 with EXO-CD24, a therapeutic directly inhaled to the lungs, as well as a broad range of disease areas, spanning ARDS, respiratory, and autoimmune diseases. Currently, the drug is in the Phase II stage of Clinical trial evaluation for the treatment of Acute Respiratory Disease Syndrome (ARDS).

* AGLE-102: Aegle Therapeutics

AGLE 102 is an allogeneic-derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material, and regenerative healing factors to diseased and damaged tissue. The drug is being developed in the Phase I/II stage of its development for the treatment of Burns and Epidermolysis bullosa dystrophica. The drug is also in the preclinical stage of its development for the Graft vs. Host Disease.

* Progenza: Cambium Bio

Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing. Adipose tissue is readily available from donors in large quantities and has significantly higher MSCs per gram of tissue than other tissue sources such as bone marrow or cord tissue. Adipose-derived MSCs also have the added advantage of showing greater capacity for expansion than MSCs from other tissue types. The MSCs are expanded through the company's proprietary and scalable manufacturing process. The company has demonstrated the capacity to produce millions of therapeutic doses of Progenza from a single donor. When Progenza cells are injected into the damaged joint or tissue, the MSCs have the potential to reduce pain and inflammation and slow the progression of disease. As per the company's pipeline, the drug is in the Phase I stage of Clinical trial evaluation for the treatment of Osteoarthritis.

* EV-101: EV Therapeutics

EV Therapeutics is a pre-clinical stage immuno-oncology biotechnology company devoted to developing first-in-class therapies based on modified tumor extracellular vesicles (mTEVs) to significantly transform cancer therapy and other unmet medical needs that are addressable with its proprietary technology platform. The leading candidate EV101, has demonstrated pre-clinical efficacy across solid tumor and advanced metastatic animal models both as a monotherapy and combination therapy with checkpoint inhibitors.

If you're tracking ongoing Exosomes Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Exosomes Treatment Drugs [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Exosomes Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes Treatment.
* Exosomes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market.

Exosomes Companies

Celularity, EVerZom, Direct Biologics, Cambium Bio, Capricor Therapeutics, Aegle Therapeutics, Organicell, Evecxia, ArunaBio, Evox, Coya Therapeutics, ILIAS Biologics, EV Therapeutics, Nano24 and others.

Exosomes Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Exosomes Products have been categorized under various Molecule types such as,

* Oligonucleotide
* Peptide
* Small molecule

From emerging drug candidates to competitive intelligence, the Exosomes Pipeline Report covers it all - check it out now @ Exosomes Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Exosomes Pipeline Report

* Coverage- Global
* Exosomes Companies- Celularity, EVerZom, Direct Biologics, Cambium Bio, Capricor Therapeutics, Aegle Therapeutics, Organicell, Evecxia, ArunaBio, Evox, Coya Therapeutics, ILIAS Biologics, EV Therapeutics, Nano24 and others.
* Exosomes Therapies- Olmutinib, Zofin, AGLE-102 , and others.
* Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Exosomes Treatment landscape in this detailed analysis @ Exosomes Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Exosomes: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Exosomes - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* ExoFlo: Direct Biologics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* EXO-CD24: Nano24
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Progenza: Cambium Bio
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* EV-101: EV Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Exosomes Key Companies
* Exosomes Key Products
* Exosomes - Unmet Needs
* Exosomes - Market Drivers and Barriers
* Exosomes - Future Perspectives and Conclusion
* Exosomes Analyst Views
* Exosomes Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=exosomes-pipeline-outlook-report-2025-emerging-therapies-clinical-developments-and-drug-insights-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/exosomes-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.